Atlas Venture Life Science Advisors LLC Purchases 1,111,111 Shares of Dyne Therapeutics, Inc. $DYN

Key Points

• Atlas Venture Life Science Advisors LLC increased its stake in Dyne Therapeutics by 13.9%, holding approximately $95.5 million, making it the firm's 3rd largest investment.
• Several institutional investors have actively transacted shares in Dyne Therapeutics, with total institutional ownership reaching 96.68%.
• Analysts have recently adjusted their price targets for Dyne Therapeutics, with a consensus target price now at $33.80, indicating ongoing interest despite fluctuations in stock ratings.

Atlas Venture Life Science Advisors LLC increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,130,465 shares of the company's stock after purchasing an additional 1,111,111 shares during the quarter. Dyne Therapeutics makes up 18.3% of Atlas Venture Life Science Advisors LLC's holdings, making the stock its 3rd largest position. Atlas Venture Life Science Advisors LLC owned about 8.03% of Dyne Therapeutics worth $95,505,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Dyne Therapeutics by 10.5% in the 1st quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock valued at $77,470,000 after purchasing an additional 702,418 shares during the period. Janus Henderson Group PLC raised its holdings in Dyne Therapeutics by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock valued at $173,808,000 after acquiring an additional 566,146 shares during the period. Jefferies Financial Group Inc. bought a new position in Dyne Therapeutics in the 4th quarter valued at about $42,408,000. Orbimed Advisors LLC raised its holdings in Dyne Therapeutics by 73.2% in the 4th quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock valued at $28,910,000 after acquiring an additional 518,680 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new position in Dyne Therapeutics in the 1st quarter valued at about $12,218,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN traded up $0.26 during mid-day trading on Wednesday, hitting $13.64. 2,184,078 shares of the company's stock were exchanged, compared to its average volume of 2,631,189. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $46.26. The stock's 50-day simple moving average is $10.27 and its 200-day simple moving average is $11.16. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -3.53 and a beta of 1.08. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.02. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on DYN shares. Raymond James Financial raised shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $31.00 to $35.00 in a report on Monday. Oppenheimer lowered their price target on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, August 6th. Sanford C. Bernstein started coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 price target on the stock. Chardan Capital lowered their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday, July 29th. Finally, Robert W. Baird lowered their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a report on Wednesday, June 18th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of "Buy" and an average target price of $34.07.

Insider Activity

In other news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, July 14th. The shares were acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.